Hepatic intra-arterial cetuximab in combination with 5-fluorouracil and cisplatin as salvage treatment for sorafenib-refractory hepatocellular carcinoma

Anticancer Research

Volumn 31, Issue 11, 2011, Pages 3927-3933

  Poggi, Guido ^a   Montagna, Benedetta ^a   Melchiorre, Fabio ^b   Quaretti, Pietro ^c   Delmonte, Angelo ^d   Riccardi, Alberto ^e   Tagliaferri, Barbara ^a   Sottotetti, Federico ^a   Di Cesare, Pamela ^a   Stella, Maria Giulia ^c   Villani, Laura ^a   Zorzetto, Michele ^c   Greco, Giorgio ^b   Cornalba, Gianpaolo ^b   Bernardo, Giovanni ^a  

^a IRCCS   (Italy)

^b SAN PAOLO HOSPITAL   (Italy)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^e UNIVERSITY OF PAVIA   (Italy)

Author keywords

Advanced hepatocellular carcinoma (HCC); Cetuximab; Hepatic intra arterial chemotherapy (HAIC)

Indexed keywords

CETUXIMAB; CISPLATIN; DOXYCYCLINE; FLUOROURACIL; PHYTOMENADIONE; SORAFENIB;

ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; EYE TOXICITY; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPOALBUMINEMIA; HYPOMAGNESEMIA; LIVER CELL CARCINOMA; LIVER FUNCTION; MALE; MULTIPLE CYCLE TREATMENT; NAIL DISEASE; NAUSEA; PANCYTOPENIA; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; SIDE EFFECT; SKIN TOXICITY; STOMATITIS; TREATMENT DURATION; XEROSIS;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FEMALE; FLUOROURACIL; HEPATIC ARTERY; HUMANS; INFUSIONS, INTRA-ARTERIAL; LIVER NEOPLASMS; MALE; MIDDLE AGED; PYRIDINES; SALVAGE THERAPY; TREATMENT OUTCOME;

EID: 83055162521     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. El-Serag HB and Rudolph KL: Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132: 2557-2576, 2007. (Pubitemid 46890874)
2. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, de Oliveira AC, Santoro A, Raoul JL, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz JF, Borbath I, Häussinger D, Giannaris T, Shan M, Moscovici M, Voliotis D and Bruix J: Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390, 2008.
3. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, Luo R, Feng J, Ye S, Yang TS, Xu J, Sun Y, Liang H, Liu J, Wang J, Tak WY, Pan H, Burock K, Zou J, Voliotis D and Guan Z: Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10: 25-34, 2009.
4. Kudo M: The 2008 Okuda lecture: Management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol 25: 439-452, 2010.
5. Itamoto T, Nakahara H, Tashiro H, Haruta N, Asahara T, Naito A and Ito K: Hepatic arterial infusion of 5-fluorouracil and cisplatin for unresectable or recurrent hepatocellular carcinoma with tumor thrombus of the portal vein. J Surg Oncol 80: 143-148, 2002. (Pubitemid 34747619)
6. Nagano H: Treatment of advanced hepatocellular carcinoma: intraarterial infusion chemotherapy combined with interferon. Oncology 78(Suppl 1): 142-147, 2010.
7. Ando E, Tanaka M, Yamashita F, Kuromatsu R, Yutani S, Fukumori K, Sumie S, Yano Y, Okuda K and Sata M: Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis: analysis of 48 cases. Cancer 95: 588-595, 2002. (Pubitemid 34810185)
8. Ensminger WD: Intrahepatic arterial infusion of chemotherapy: pharmacologic principles. Semin Oncol 29: 119-125, 2002.
9. Daveau M, Scotte M, François A, Coulouarn C, Ros G, Tallet Y, Hiron M, Hellot MF and Salier JP: Hepatocyte growth factor, transforming growth factor alpha, and their receptors as combined markers of prognosis in hepatocellular carcinoma. Mol Carcinog 36: 130-141, 2003. (Pubitemid 36314790)
10. Ito Y, Takeda T, Sakon M, Tsujimoto M, Higashiyama S, Noda K, Miyoshi E, Monden M and Matsuura N: Expression and clinical significance of erb-B receptor family in hepatocellular carcinoma. Br J Cancer 84: 1377-1383, 2001. (Pubitemid 32522107)
11. DeCicco LA, Kong J and Ringer DP: Carcinogen-induced alteration in liver epidermal growth factor receptor distribution during the promotion stage of hepatocarcinogenesis in rat. Cancer Lett 111: 149-156, 1997. (Pubitemid 27068230)
12. Carter P: Improving the efficacy of antibody-based cancer therapies. Nat Rev Cancer 1: 118-129, 2001.
13. Zhu AX, Stuart K, Blaszkowsky LS, Muzikansky A, Reitberg DP, Clark JW, Enzinger PC, Bhargava P, Meyerhardt JA, Horgan K, Fuchs CS and Ryan DP: Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 110: 581-589, 2007. (Pubitemid 47106147)
14. Asnacios A, Fartoux L, Romano O, Tesmoingt C, Louafi S S, Mansoubakht T, Artru P, Poynard T, Rosmorduc O, Hebbar M and Taieb J: Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 112: 2733-2739, 2008. (Pubitemid 351969218)
15. Bruix J and Sherman M: Management of hepatocellular carcinoma. Hepatology 42: 1208-1236, 2005. (Pubitemid 43112690)
16. Child CG and Turcotte JG: Surgery and portal hypertension. Major Probl Clin Surg 1: 1-85, 1964.
17. Llovet JM, Bru C and Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19: 329-338, 1999.
18. Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 31: 840-845, 2000.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC and Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92: 205-216, 2000.
20. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS and Störkel S: Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52: 893-901, 2004. (Pubitemid 38857154)
21. Hall TA: BioEdit: A user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucl. Acids. Symp. Ser. 41:95-98, 1999.
22. Huether A, Höpfner M, Baradari V, Schuppan D and Scherübl H: EGFR blockade by cetuximab alone or as combination therapy for growth control of hepatocellular cancer. Biochem Pharmacol 70: 1568-1578, 2005. (Pubitemid 41540350)
23. Llovet JM: Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 40: 225-235, 2005.
24. Yeo W, Mok TS, Zee B, Leung TW, Lai PB, Lau WY, Koh J, Mo FK, Yu SC, Chan AT, Hui P, Ma B, Lam KC, Ho WM, Wong HT, Tang A and Johnson PJ: A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/ fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 97: 1532-1538, 2005. (Pubitemid 41631953)
25. Breedis C and Young G: The blood supply of neoplasms in the liver. Am J Pathol 30: 969-977, 1954.
26. Ackerman NB: The blood supply of experimental liver metastases. IV. Changes in vascularity with increasing tumor growth. Surgery 75: 589-596, 1974.
27. Shao YY, Huang CC, Liang PC and Lin ZZ: Hepatic arterial infusion of chemotherapy for advanced hepatocellular carcinoma. Asia Pac J Clin Oncol 6: 80-88, 2010.
28. Tabernero J, Pfeiffer P and Cervantes A: Administration of cetuximab every 2 weeks in the treatment of metastatic colorectal cancer: an effective, more convenient alternative to weekly administration? Oncologist 13: 113-119, 2008. (Pubitemid 351342574)
29. Vincenzi B, Santini D, Russo A, Silletta M, Gavasci M, Battistoni F, Di Cuonzo G, Rocci L, Gebbia N and Tonini G: Angiogenesis modifications related with cetuximab plus irinotecan as anticancer treatment in advanced colorectal cancer patients. Ann Oncol 17: 835-841, 2006.